Semaglutide and the risk of pancreatitis: what the evidence says

You've started Wegovy and your stomach hurts, here's how to tell what matters

Nausea and some general stomach discomfort are common in the first weeks of Wegovy, particularly after starting or stepping up a dose. Most people find it settles. But there is a distinct symptom that should never be put down to ordinary side effects: severe, persistent abdominal pain that extends towards the back, sometimes accompanied by vomiting, that does not ease. That pattern is a recognised signal for acute pancreatitis and it needs same-day emergency assessment, call 999 or go straight to A&E.

A question our prescribers hear most weeks is whether stomach pain during treatment is something to wait out or something to act on. The honest answer is that mild, cramping or nausea-type discomfort can reasonably be managed with small meals and hydration, as your Patient Information Leaflet describes. Pain that is severe, radiates to your back, or is getting steadily worse is a different conversation entirely. The MHRA's Drug Safety Updates are unambiguous on this: if pancreatitis is suspected, stop the medicine and seek urgent care.

The broader picture of what semaglutide can and cannot cause is covered in detail on our Wegovy side effects page, including the gastrointestinal effects that are far more common and far less serious than pancreatitis.

What the evidence actually shows about pancreatitis and semaglutide

The risk of pancreatitis with Wegovy is classified as infrequent in the SmPC, meaning it occurs in fewer than 1 in 100 but more than 1 in 1,000 people taking the medicine. That is not zero, and it is not trivial if you are the person affected. The MHRA's January 2026 Drug Safety Update confirmed that the signal exists across the GLP-1 class, that prescribers should counsel patients on the warning signs before starting, and that treatment should be stopped if pancreatitis is confirmed or strongly suspected.

Separately, there is a pre-existing risk to consider. People who have had pancreatitis before, or who have conditions closely associated with it (such as gallstones or significantly elevated triglycerides) may carry a higher baseline risk. The Wegovy SmPC, which you can review in full on the Electronic Medicines Compendium, lists a history of pancreatitis among the factors a prescriber must weigh before initiating treatment.

The deeper question of whether semaglutide directly causes pancreatitis or simply occurs alongside it in a population with overlapping risk factors is still being studied. For patients, the practical point is simpler: the MHRA has identified it as a real risk, clinical guidance treats it as one, and if you want to understand the warning signs before you pick up your first pen, our guide to Wegovy and pancreatitis is a good place to start. Our detailed page on pancreatitis caused by Wegovy works through the evidence and the causality debate in more depth.

When to get medical help, and what not to dismiss

Go to A&E or call 999 immediately if you develop severe pain in the upper abdomen or around the middle of the back that does not ease, particularly if it is accompanied by vomiting. Do not wait to see if it passes. That is the guidance from the NHS's patient information on semaglutide, and it reflects the clinical reality that acute pancreatitis can escalate quickly.

Less urgent but still worth a GP call: pain that is moderate and lingering rather than severe; jaundice; or any symptoms that feel unusual and don't fit the standard GI pattern you were told to expect. Your prescriber and the Patient Information Leaflet in your pen box are the right reference points for anything that sits in the grey area.

If you experience something you think may be a side effect of semaglutide, including anything that might point to pancreatitis, you can report it via the MHRA's Yellow Card scheme. Patients can do this directly, no referral needed. These reports genuinely contribute to ongoing medicine safety monitoring.

For those weighing whether to start Wegovy or thinking through their specific risk factors, our prescribers discuss suitability and side effects in detail as part of the free consultation. You can start your free consultation here if you'd like a clinician to review your full picture before you decide.

Reducing your risk: what you can do before and during treatment

There is no guaranteed way to prevent pancreatitis, but there are steps that are consistent with the guidance for reducing pancreatitis risk on Wegovy. Staying well hydrated throughout treatment matters, semaglutide slows gastric emptying, and dehydration from GI side effects can stress the pancreas. Alcohol in excess is an independent risk factor for pancreatitis and sits poorly alongside GLP-1 treatment in general. If you have a history of gallstones, elevated triglycerides or prior pancreatic problems, tell your prescriber before starting.

The titration schedule (beginning at 0.25mg and stepping up gradually under clinical supervision) exists partly to give your body time to adjust. Skipping doses or escalating faster than advised is not only unsupported clinically; it removes the safety buffer that slow titration provides. Follow the schedule your prescriber has set, and flag any persistent GI symptoms rather than tolerating them.

Anyone wanting a closer read on the practical steps is also covered in our guide on how to avoid pancreatitis on Wegovy, which walks through the lifestyle and monitoring considerations in full.